Recent News

• 04.08.2025 - Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
• 04.08.2025 - Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
• 02.28.2025 - Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
• 02.28.2025 - Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
• 02.19.2025 - Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
• 02.19.2025 - Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Recent Filings

• 04.08.2025 - 8-K Current report
• 03.28.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 03.28.2025 - EFFECT Notice of Effectiveness
• 03.20.2025 - S-3 Registration statement under Securities Act of 1933
• 03.14.2025 - 8-K Current report
• 03.12.2025 - 4/A Statement of changes in beneficial ownership of securities
• 03.12.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 03.07.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 03.07.2025 - EFFECT Notice of Effectiveness
• 03.05.2025 - CORRESP Correspondence